Recommendation for the diagnosis and management of immune checkpoint inhibitor related infections
Immune checkpoint inhibitors (ICIs) have been widely used in the management of malignant tumors. Programmed death 1 (PD‐1)/PD‐1 ligand (PD‐L1) inhibitors have been introduced to treat non‐small cell lung cancer (NSCLC) in recent years. Currently, PD‐1/PD‐L1 inhibitors are considered to have minor si...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-03-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.13313 |
| _version_ | 1818380023616241664 |
|---|---|
| author | Minya Lu Li Zhang Yue Li Hanping Wang Xiaoxiao Guo Jiaxin Zhou Lian Duan Xiaoyan Si Yingchun Xu Li Zhang |
| author_facet | Minya Lu Li Zhang Yue Li Hanping Wang Xiaoxiao Guo Jiaxin Zhou Lian Duan Xiaoyan Si Yingchun Xu Li Zhang |
| author_sort | Minya Lu |
| collection | DOAJ |
| description | Immune checkpoint inhibitors (ICIs) have been widely used in the management of malignant tumors. Programmed death 1 (PD‐1)/PD‐1 ligand (PD‐L1) inhibitors have been introduced to treat non‐small cell lung cancer (NSCLC) in recent years. Currently, PD‐1/PD‐L1 inhibitors are considered to have minor side effects and do not independently increase the risk of infection. However, they may cause immune‐related adverse events (irAEs) that require immunosuppressive therapy with corticosteroids and/or immunosuppressants, leading to opportunistic infections. Furthermore, there have been reports describing reactivation of chronic/latent infections without irAEs or having received immunosuppressants. Thus, immune checkpoint inhibitor related infections have received more attention worldwide. In this paper, we review available clinical data, describe the potential mechanism, and propose recommendations for the diagnosis and clinical management of PD‐1/PD‐L1 inhibitor‐related infections. |
| first_indexed | 2024-12-14T02:12:05Z |
| format | Article |
| id | doaj.art-395359cf6b464169bfa8f14cf5f038de |
| institution | Directory Open Access Journal |
| issn | 1759-7706 1759-7714 |
| language | English |
| last_indexed | 2024-12-14T02:12:05Z |
| publishDate | 2020-03-01 |
| publisher | Wiley |
| record_format | Article |
| series | Thoracic Cancer |
| spelling | doaj.art-395359cf6b464169bfa8f14cf5f038de2022-12-21T23:20:44ZengWileyThoracic Cancer1759-77061759-77142020-03-0111380580910.1111/1759-7714.13313Recommendation for the diagnosis and management of immune checkpoint inhibitor related infectionsMinya Lu0Li Zhang1Yue Li2Hanping Wang3Xiaoxiao Guo4Jiaxin Zhou5Lian Duan6Xiaoyan Si7Yingchun Xu8Li Zhang9Department of Laboratory Medicine, Peking Union Medical College Hospital Chinese Academy of Medical Sciences Beijing ChinaDepartment of Laboratory Medicine, Peking Union Medical College Hospital Chinese Academy of Medical Sciences Beijing ChinaDepartment of Gastroenterology, Peking Union Medical College Hospital Chinese Academy of Medical Sciences Beijing ChinaDepartment of Respirology, Peking Union Medical College Hospital Chinese Academy of Medical Sciences Beijing ChinaDepartment of Cardiology, Peking Union Medical College Hospital Chinese Academy of Medical Sciences Beijing ChinaDepartment of Rheumatology and Immunology, Peking Union Medical College Hospital Chinese Academy of Medical Sciences Beijing ChinaDepartment of Endocrinology, Peking Union Medical College Hospital Chinese Academy of Medical Sciences Beijing ChinaDepartment of Respirology, Peking Union Medical College Hospital Chinese Academy of Medical Sciences Beijing ChinaDepartment of Laboratory Medicine, Peking Union Medical College Hospital Chinese Academy of Medical Sciences Beijing ChinaDepartment of Respirology, Peking Union Medical College Hospital Chinese Academy of Medical Sciences Beijing ChinaImmune checkpoint inhibitors (ICIs) have been widely used in the management of malignant tumors. Programmed death 1 (PD‐1)/PD‐1 ligand (PD‐L1) inhibitors have been introduced to treat non‐small cell lung cancer (NSCLC) in recent years. Currently, PD‐1/PD‐L1 inhibitors are considered to have minor side effects and do not independently increase the risk of infection. However, they may cause immune‐related adverse events (irAEs) that require immunosuppressive therapy with corticosteroids and/or immunosuppressants, leading to opportunistic infections. Furthermore, there have been reports describing reactivation of chronic/latent infections without irAEs or having received immunosuppressants. Thus, immune checkpoint inhibitor related infections have received more attention worldwide. In this paper, we review available clinical data, describe the potential mechanism, and propose recommendations for the diagnosis and clinical management of PD‐1/PD‐L1 inhibitor‐related infections.https://doi.org/10.1111/1759-7714.13313Immune checkpointimmune‐related adverse eventsinfectionsPD‐1/PD‐L1 inhibitors |
| spellingShingle | Minya Lu Li Zhang Yue Li Hanping Wang Xiaoxiao Guo Jiaxin Zhou Lian Duan Xiaoyan Si Yingchun Xu Li Zhang Recommendation for the diagnosis and management of immune checkpoint inhibitor related infections Thoracic Cancer Immune checkpoint immune‐related adverse events infections PD‐1/PD‐L1 inhibitors |
| title | Recommendation for the diagnosis and management of immune checkpoint inhibitor related infections |
| title_full | Recommendation for the diagnosis and management of immune checkpoint inhibitor related infections |
| title_fullStr | Recommendation for the diagnosis and management of immune checkpoint inhibitor related infections |
| title_full_unstemmed | Recommendation for the diagnosis and management of immune checkpoint inhibitor related infections |
| title_short | Recommendation for the diagnosis and management of immune checkpoint inhibitor related infections |
| title_sort | recommendation for the diagnosis and management of immune checkpoint inhibitor related infections |
| topic | Immune checkpoint immune‐related adverse events infections PD‐1/PD‐L1 inhibitors |
| url | https://doi.org/10.1111/1759-7714.13313 |
| work_keys_str_mv | AT minyalu recommendationforthediagnosisandmanagementofimmunecheckpointinhibitorrelatedinfections AT lizhang recommendationforthediagnosisandmanagementofimmunecheckpointinhibitorrelatedinfections AT yueli recommendationforthediagnosisandmanagementofimmunecheckpointinhibitorrelatedinfections AT hanpingwang recommendationforthediagnosisandmanagementofimmunecheckpointinhibitorrelatedinfections AT xiaoxiaoguo recommendationforthediagnosisandmanagementofimmunecheckpointinhibitorrelatedinfections AT jiaxinzhou recommendationforthediagnosisandmanagementofimmunecheckpointinhibitorrelatedinfections AT lianduan recommendationforthediagnosisandmanagementofimmunecheckpointinhibitorrelatedinfections AT xiaoyansi recommendationforthediagnosisandmanagementofimmunecheckpointinhibitorrelatedinfections AT yingchunxu recommendationforthediagnosisandmanagementofimmunecheckpointinhibitorrelatedinfections AT lizhang recommendationforthediagnosisandmanagementofimmunecheckpointinhibitorrelatedinfections |